Brain amyloid-β (Aβ) deposition is a hallmark to define Alzheimer’s disease (AD). We investigated the positive rate of brain amyloid deposition assessed with 11C-Pittsburgh compound (PiB)-PET and blood Aβ levels in a cohort of probable AD patients who were diagnosed according to the 1984 NINCDS-ADRDA criteria. Eighty-four subjects with a clinical diagnosis of probable AD dementia, amnestic mild cognitive impairment (MCI), and cognitively normal (CN) status were subjected to PiB-PET and 18F-fluorodeoxyglucose (FDG)-PET scans. Plasma biomarkers of Aβ42, Aβ40, and T-tau were measured using single molecule array technology. The positive rate of PiB-PET, the associations between PiB-PET status and FDG-PET, plasma biomarkers, and clinical manifestations were analyzed. PiB-PET was positive in 77.36% of probable AD patients, 31.80% of MCI patients, and 0 of NC. Plasma Aβ42/Aβ40 ratio was associated with PiB-PET, the ROC curve analysis revealing an AUC of 0.77 (95% CI: 0.66–0.87), with a sensitivity of 82% and specificity of 64%. Some clinical manifestations were associated with PiB-PET imaging. Our findings indicate that only three-fourths of patients diagnosed with probable AD fit the pathological criteria, suggesting that we should be cautious regarding the accuracy of AD diagnosis when no biomarker evidence is available in our clinical practice.
PascoalTA, MathotaarachchiS, MohadesS, BenedetAL, ChungCO, ShinM, WangS, BeaudryT, KangMS, SoucyJP, LabbeA, GauthierS, Rosa-NetoP (2017) Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer’s disease. Mol Psychiatry22, 306–311.
2.
WangQH, WangX, BuXL, LianY, XiangY, LuoHB, ZouHQ, PuJ, ZhouZH, CuiXP, WangQS, ShiXQ, HanW, WuQ, ChenHS, LinH, GaoCY, ZhangLL, XuZQ, ZhangM, ZhouHD, WangYJ (2017) Comorbidity burden of dementia: a hospital-based retrospective study from 2003 to 2012 in seven cities in China. Neurosci Bull33, 703–710.
3.
HymanBT, TrojanowskiJQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol56, 1095–1097.
4.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT, National Institute on Aging, Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol123, 1–11.
5.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
6.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
7.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
VillemagneVL, DoreV, BurnhamSC, MastersCL, RoweCC (2018) Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol14, 225–236.
11.
SunBL, LiWW, ZhuC, JinWS, ZengF, LiuYH, BuXL, ZhuJ, YaoXQ, WangYJ (2018) Clinical research on Alzheimer’s disease: progress and perspectives. Neurosci Bull34, 1111–1118.
12.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH, Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement9, e1–16.
ZengF, ZouHQ, ZhouHD, LiJ, WangL, CaoHY, YiX, WangX, LiangCR, WangYR, ZhangAQ, TanXL, PengKR, ZhangLL, GaoCY, XuZQ, WenAQ, LianY, ZhouXF, WangYJ (2013) The relationship between single nucleotide polymorphisms of the NTRK2 gene and sporadic Alzheimer’s disease in the Chinese Han population. Neurosci Lett550, 55–59.
15.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
16.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
17.
MorrisJC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology43, 2412–2414.
18.
O’BryantSE, LacritzLH, HallJ, WaringSC, ChanW, KhodrZG, MassmanPJ, HobsonV, CullumCM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer’s coordinating center database. Arch Neurol67, 746–749.
19.
PfeifferE (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc23, 433–441.
20.
HachinskiVC, IliffLD, ZilhkaE, Du BoulayGH, McAllisterVL, MarshallJ, RussellRW, SymonL (1975) Cerebral blood flow in dementia. Arch Neurol32, 632–637.
21.
HarperL, FumagalliGG, BarkhofF, ScheltensP, O’BrienJT, BouwmanF, BurtonEJ, RohrerJD, FoxNC, RidgwayGR, SchottJM (2016) MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain139, 1211–1225.
Zhang ZXHX, LiH, ZhaoJH, HuangJB, WeiJ, WangJM, LS, YangEL, WuJX, JiCJ, WangXD (1999) The minimental state examination in the Chinese residents population aged 55 years and over in the urban and rural areas of Beijing.pdf. Chin J Neurol32, 149–153.
24.
TanJP, LiN, GaoJ, WangLN, ZhaoYM, YuBC, DuW, ZhangWJ, CuiLQ, WangQS, LiJJ, YangJS, YuJM, XiaXN, ZhouPY (2015) Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal Cognitive Assessment among elderly and oldest-old Chinese population. J Alzheimers Dis43, 1403–1412.
25.
LoprestiBJ, KlunkWE, MathisCA, HogeJA, ZiolkoSK, LuX, MeltzerCC, SchimmelK, TsopelasND, DeKoskyST, PriceJC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med46, 1959–1972.
26.
GrimmerT, DiehlJ, DrzezgaA, ForstlH, KurzA (2004) Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord18, 32–36.
27.
OssenkoppeleR, PrinsND, PijnenburgYA, LemstraAW, van der FlierWM, AdriaanseSF, WindhorstAD, HandelsRL, WolfsCA, AaltenP, VerheyFR, VerbeekMM, van BuchemMA, HoekstraOS, LammertsmaAA, ScheltensP, van BerckelBN (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement9, 414–421.
28.
Sanchez-JuanP, GhoshPM, HagenJ, GesierichB, HenryM, GrinbergLT, O’NeilJP, JanabiM, HuangEJ, TrojanowskiJQ, VintersHV, Gorno-TempiniM, SeeleyWW, BoxerAL, RosenHJ, KramerJH, MillerBL, JagustWJ, RabinoviciGD (2014) Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology82, 230–238.
29.
WilkeC, BenderF, HayerSN, BrockmannK, ScholsL, KuhleJ, SynofzikM (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol265, 1618–1624.
30.
YangL, RievesD, GanleyC (2012) Brain amyloid imaging–FDA approval of florbetapir F18 injection. N Engl J Med367, 885–887.
31.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
32.
DegenhardtEK, WitteMM, CaseMG, YuP, HenleyDB, HochstetlerHM, D’SouzaDN, TrzepaczPT (2016) Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics57, 208–216.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ; Amyloid PET Study Group, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sánchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChételatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA313, 1939–1949.
35.
de WildeA, van der FlierWM, PelkmansW, BouwmanF, VerwerJ, GrootC, van BuchemMM, ZwanM, OssenkoppeleR, YaqubM, KunnemanM, SmetsEMA, BarkhofF, LammertsmaAA, StephensA, van LierE, BiesselsGJ, van BerckelBN, ScheltensP (2018) Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: The ABIDE Project. JAMA Neurol75, 1062–1070.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
38.
JiaJ, ZuoX, JiaXF, ChuC, WuL, ZhouA, WeiC, TangY, LiD, QinW, SongH, MaQ, LiJ, SunY, MinB, XueS, XuE, YuanQ, WangM, HuangX, FanC, LiuJ, RenY, JiaQ, WangQ, JiaoL, XingY, WuX, China Cognition and Aging Study (China COAST) Group (2016) Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. Alzheimers Dement12, 446–453.
39.
VerberkIMW, SlotRE, VerfaillieSCJ, HeijstH, PrinsND, van BerckelBNM, ScheltensP, TeunissenCE, Van der FlierWM (2018) Plasma amyloid as pre-screener for the earliest Alzheimer’s pathological changes. Ann Neurol84, 648–658.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundLO, NordbergA, BackmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
42.
VisserPJ, KesterA, JollesJ, VerheyF (2006) Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology67, 1201–1207.
43.
Malek-AhmadiM (2016) Reversion from mild cognitive impairment to normal cognition: a meta-analysis. Alzheimer Dis Assoc Disord30, 324–330.
44.
ScheltensP, BlennowK, BretelerMM, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–517.
